Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels

Nutrition

Volumn 26, Issue 10, 2010, Pages 975-980

  Onat, Altan ^a,b   Kömürcü Bayrak, Evrim ^b   Can, Günay ^b   Küçükdurmaz, Zekeriya ^c   Hergenç, Gülay ^d   Erginel Unaltuna, Nihan ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Apolipoprotein E genotype; Apolipoproteins A I, B, and E; Diabetes type 2; Gender difference; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TURKEY (REPUBLIC);

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEX FACTORS; TRIGLYCERIDES; TURKEY;

EID: 77957260775     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.09.023     Document Type: Article

References (29)

1. Dallongeville J., Lussier-Cacan S., Davignon S. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
2. Liu S., Ma J., Ridker P.M., Breslow J.L., Stampfer M.J. A prospective study of the APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2004, 166:323-329.
3. Bennet A.M., Di Angelantonio E., Ye Z., Wensley F., Dahlin A., Ahlbom A., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298:1300-1311.
4. Mänttäri M., Manninen V., Palosuo T., Ehnholm C. Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men (letter). Atherosclerosis 2001, 156:237-238.
5. Austin M.A., Zhang C., Humphries S.E., Chandler W.L., Talmud P.J., Edwards K.L., et al. Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. Ann Hum Genet 2004, 68:179-188.
6. Judson R., Brain C., Dain B., Windemuth A., Ruano G., Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004, 177:345-351.
7. Eiriksdottir G., Aspelund T., Bjarnadottir K., Olafsdottir E., Gudnason V. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES Reykjavik Study (letter). Atherosclerosis 2006, 186:222-224.
8. Errera F.I.V., Silva M.E.R., Yeh E., Maranduba C.M.C., Folco B., Takahashi W., et al. Effect of polymorphism of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazialian patients. Braz J Med Biol Res 2006, 39:883-888.
9. Onat A., Hergenç G., Can G. Serum C-reactive protein as an independent risk factor predicting cardiometabolic risk. Metabolism 2008, 57:207-214.
10. Onat A., Can G., Hergenç G. Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes Relat Metab Disord 2007, 31:1119-1125.
11. Onat A., Hergenç G., Bulur S. Uĝur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2008, 135:211-217.
12. Onat A., Can G., Ayhan E., Kaya Z., Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009, 58:1393-1399.
13. Onat A., Hergenç G., Can G., Küçükdurmaz Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity 2008, 17:564-570.
14. Schiele F., De Bacquer D., Vincent-Viry M., Beisiegel U., Ehnholm C., Evans A., et al. The ApoEurope group. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000, 152:475-488.
15. Schiele F., Vincent-Viry M., Starck M., Beaud B., Hennache G., Siest G., et al. Apolipoprotein E in apolipoprotein B (apo B)- and non-apo B-containing lipoproteins in 3523 participants in the Stanislas Cohort: biological variation and genotype-specific reference limits. Clin Chem 2002, 48:291-300.
16. Boerwinkle E., Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 1988, 42:104-112.
17. Zerba K.E., Ferrell R.E., Sing C.F. Complex adaptive systems and human health: the influence of common genotypes of the apolipoprotein E (apoE) gene polymorphism and age on the relational order within a field of lipid metabolism traits. Hum Genet 2000, 107:466-485.
18. Onat A., Ceyhan K., Başar Ö, Erer B., Toprak S., Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002, 165:285-292.
19. Onat A., Avci GŞ, Şenocak M., Örnek E., Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidemiol Community Health 1992, 46:470-476.
20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
21. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
22. Onat A., Uyarel H., Hergenç G., Karabulut A., Albayrak S., Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
23. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:3160-3167.
24. Mahley R.W., Palaoĝlu E., Atak Z., Dawson-Pepin J., Langlois A.M., Cheung V., et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995, 36:839-859.
25. Ogasawara K., Mashiba S., Hashimoto H., Kojima S., Matsuno S., Takeya M., et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008, 397:42-47.
26. Onat A., Hergenç G., Ayhan E., Kaya Z., Küçükdurmaz Z., Bulur S., et al. Serum apolipoprotein E concentrations among Turks: additive information to genotype relative to dyslipidemia and metabolic syndrome. Arch Turk Soc Cardiol 2007, 35:449-457.
27. Morcillo S., Cardona F., Rojo-Martinez G., Esteva I., Ruiz-de-Adana M.S., Tinahones F., et al. Association between MspI polymorphism of the APO AI gene and type 2 diabetes mellitus. Diabet Med 2005, 22:782-788.
28. Dodin S., Cunnane S.C., Masse B., Lemay A., Jacques H., Asselin G., et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutrition 2008, 24:23-30.
29. Greenow K., Pearce N.J., Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J Mol Med 2005, 83:329-342.